Penumbra Inc PEN
We take great care to ensure that the data presented and summarized in this overview for Penumbra Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PEN
View all-
Black Rock Inc. New York, NY4.26MShares$1.09 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.68MShares$941 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.21MShares$309 Million0.04% of portfolio
-
State Street Corp Boston, MA1.2MShares$307 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT870KShares$223 Million1.79% of portfolio
-
Rtw Investments, LP New York, NY863KShares$221 Million3.78% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il784KShares$201 Million0.04% of portfolio
-
Jpmorgan Chase & CO New York, NY704KShares$180 Million0.01% of portfolio
-
Baillie Gifford & CO689KShares$176 Million0.17% of portfolio
-
Geode Capital Management, LLC Boston, MA689KShares$176 Million0.01% of portfolio
Latest Institutional Activity in PEN
Top Purchases
Top Sells
About PEN
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Insider Transactions at PEN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 16
2025
|
Bridget O'Rourke Director |
SELL
Open market or private sale
|
Direct |
50
-0.92%
|
$12,950
$259.78 P/Share
|
Jun 11
2025
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Direct |
15,910
-2.19%
|
$4,025,230
$253.5 P/Share
|
Jun 11
2025
|
Adam Elsesser CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
27,976
+18.14%
|
$839,280
$30.0 P/Share
|
Jun 02
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.08%
|
$156,600
$261.28 P/Share
|
May 28
2025
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Direct |
16,300
-1.38%
|
$4,368,400
$268.48 P/Share
|
May 28
2025
|
Adam Elsesser CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
27,976
+19.62%
|
$839,280
$30.0 P/Share
|
May 21
2025
|
Adam Elsesser CEO and President |
SELL
Bona fide gift
|
Indirect |
260,000
-31.04%
|
-
|
May 15
2025
|
Bridget O'Rourke Director |
SELL
Open market or private sale
|
Direct |
100
-1.81%
|
$28,600
$286.15 P/Share
|
May 14
2025
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Direct |
16,600
-2.81%
|
$4,913,600
$296.28 P/Share
|
May 14
2025
|
Adam Elsesser CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
27,976
+21.33%
|
$839,280
$30.0 P/Share
|
May 12
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
900
-0.15%
|
$266,400
$296.91 P/Share
|
May 12
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
55
+0.08%
|
$1,210
$22.04 P/Share
|
May 07
2025
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Direct |
16,650
-2.45%
|
$4,828,500
$290.94 P/Share
|
May 07
2025
|
Adam Elsesser CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
27,976
+23.34%
|
$839,280
$30.0 P/Share
|
May 06
2025
|
Maggie Yuen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+5.71%
|
$142,200
$158.3 P/Share
|
May 02
2025
|
Maggie Yuen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-12.53%
|
$598,000
$299.01 P/Share
|
Apr 25
2025
|
Arani Bose Director |
SELL
Open market or private sale
|
Direct |
12,000
-0.32%
|
$3,588,000
$299.39 P/Share
|
Apr 24
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.9%
|
$180,000
$300.01 P/Share
|
Apr 24
2025
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+0.89%
|
$13,200
$22.04 P/Share
|
Apr 16
2025
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Direct |
16,560
-3.22%
|
$4,537,440
$274.69 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 22K shares |
---|---|
Exercise of conversion of derivative security | 306K shares |
Open market or private sale | 342K shares |
---|---|
Payment of exercise price or tax liability | 3.87K shares |
Bona fide gift | 260K shares |